To Be Discontinued Transdermal System Gastroenterology
Scopolamine Transdermal Syst · 311 days since initial FDA posting
Brand: SCOPOLAMINE TRANSDERMAL SYSTEM
FDA lists Scopolamine Transdermal Syst as To Be Discontinued (Padagis US LLC).
No availability text on this FDA row.
Scopolamine Transdermal System: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Scopolamine Transdermal System
- Manufacturer
- Padagis US LLC
- Dosage Form
- Transdermal System
- Presentation
- Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)
- Package NDC
- 45802-580-46
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Nov 3, 2025
- Last Updated
- Nov 3, 2025
- Therapeutic Category
- Gastroenterology, Neurology, Other
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.